Moximed snagged $40 million as it works to secure approval for its device, an implantable shock absorber for the knee designed to put off the need for full joint replacement. CEO Anton Clifford touts that the MISHA Knee System is the first of its kind.
The collaboration includes six drugs in development and more than 20 in preclinical development. It also amends an existing four-year-old partnership the two companies had regarding the autoimmune disease drug filgotinib.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Despite being just four years old, Centrexion, which just raised $67 million, is building a significant pipeline of non-opioid, non-steroidal pain medications.
The company will use most of the new funding to build up its sales, business development and marketing operations, with the goal of fully entering the U.S. market by the second quarter of 2017.
Swedish startup Jojnts has developed a digital version of a national program to help people diagnosed with osteoarthritis better manage their condition. The idea is that by providing an app for the program the company will be able to find a global audience in search of a way to treat osteoarthritis in a way that […]
Drug development companies have developed innovative approaches to drug formulation to avoid or reduce the adverse events that accompany pain management drugs. Iroko Pharmaceuticals has been building a portfolio of low dose Non Steroidal Anti Inflammatory Drugs. It presented data from a Phase 3 trial of its osteoarthritis drug SoluMatrix Meloxicam at the Annual European […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.